Bio Plus Co., Ltd (KOSDAQ:099430)

South Korea · Delayed Price · Currency is KRW

3,475.00

-5.00 (-0.14%)

Aug 20, 2026, 3:30 PM KST

-43.13% (1Y)

Market Cap	213.85B -42.4%
Revenue (ttm)	94.42B +18.4%
Net Income	14.00B -28.6%
EPS	138.98 -58.6%
Shares Out	61.54M
PE Ratio	25.00
Forward PE	n/a
Dividend	70.00 (2.01%)
Ex-Dividend Date	Dec 29, 2025

Volume	302,026
Open	3,545.00
Previous Close	3,480.00
Day's Range	3,445.00 - 3,675.00
52-Week Range	3,065.00 - 7,350.00
Beta	0.59
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About Bio Plus

Bio Plus Co., Ltd engages in the research and development, production, and sale of bio products in South Korea. It offers dermal fillers under the SkinPlus – Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses brand names. The company also provides medical products, including InterBlock, an absorbable anti-adhesion barrier; Synofil, a synovial fluid replacement; and Blad-Care, a solution to temporarily improve cystitis symptoms. In addition, it offers mesotherapy products, such as skin rejuvenation products under the Kiara Reju name; S... [Read more]

Industry Medical - Specialties

Sector Healthcare

Founded 2003

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 099430

Full Company Profile

Financial Performance

In 2025, Bio Plus's revenue was 90.90 billion, an increase of 36.87% compared to the previous year's 66.41 billion. Earnings were 15.00 billion, an increase of 6.01%.

Financial Statements